Clonal Origin of Hepatocellular Carcinoma and Recurrence After Liver Transplantation

被引:4
|
作者
Wang, Zhenglu [1 ,2 ,3 ]
Gong, Weihua [4 ]
Shou, Dawei [4 ]
Zhang, Luzhou [5 ]
Gu, Xiangqian [6 ]
Wang, Yuliang [2 ]
Teng, Dahong [1 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Tianjin First Ctr Hosp, Orient Organ Transplant Ctr, Tianjin, Peoples R China
[2] Tianjin First Ctr Hosp, Key Lab Crit Care Med, Minist Hlth, Tianjin, Peoples R China
[3] Tianjin Key Lab Organ Transplantat, Tianjin, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Surg, Hangzhou, Zhejiang, Peoples R China
[5] Peoples Hosp Zhucheng City, Zhucheng, Shandong, Peoples R China
[6] Tianjin Med Univ, Cent Clin Inst 1, Tianjin, Peoples R China
关键词
Carcinoma; Hepatocellular; Liver Transplantation; Loss of Heterozygosity; Neoplasm Recurrence; Local; CANCER STEM-CELLS; INTRAHEPATIC METASTASIS; MULTICENTRIC ORIGIN; HETEROZYGOSITY; MULTIPLE; RESECTION; HEPATOCARCINOGENESIS; MICROSATELLITES; SURVIVAL;
D O I
10.12659/AOT.899572
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: This study aimed to determine whether patterns of tumor clonal origin in pluri-nodular hepatocellular carcinoma (PNHC) could serve as an indicator of tumor recurrence following liver transplantation. Material/Methods: Tumor tissue samples from 60 PNHC patients who underwent liver transplantation were examined. The diagnosis of patients conformed to the University of California San Francisco (UCSF) standards for pluri-nodular hepatocellular carcinoma. We performed loss of heterozygosity tests at multiple microsatellite sites to determine the clonal origins of the tumors. Clinical information, pathological data, preoperative serum alpha-feto protein (AFP) and postoperative follow-ups were obtained and correlations between the clonal origin of the tumor, tumor-free survival, pathological characteristics, and AFP levels in serum were studied. Results: A total of 165 tumor nodules were collected. Tumor clonal origins were identified as intrahepatic metastasis (IM; 41.67%), multicentric occurrence (MO; 55%) or unidentified (3.33%). Three-year tumor-free survival for the IM group was 48% compared to 75.76% in the MO group (p<0.05), while the occurrence of microscopic tumor thrombus was 100% and 3.03% (p<0.05) for these groups, respectively. The degree of tumor differentiation was 80% for the IM group and 18.18% for the MO group (p<0.05), while the mean AFP concentration for these groups was 226.80 mu g/L (2.78-3000 mu g/L) and 24.59 mu g/L (1.16-531. 30 mu g/L; p<0.05), respectively. Conclusions: Clonal origin patterns can serve as important indicators to predict the recurrence of PNHC following liver transplantation. Taken together with pathological characteristics and preoperative serum AFP levels, the risk of recurrence can be established in advance.
引用
收藏
页码:484 / 490
页数:7
相关论文
共 50 条
  • [41] Effect of cyclosporine on hepatocellular carcinoma recurrence after liver transplantation.
    Vivarelli, M
    Cucchetti, A
    La Barba, G
    Cavallari, A
    Pinna, AD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 368 - 368
  • [42] Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
    Perera, S.
    Magyar, C. T. J.
    Rajendran, L.
    Li, Z.
    Almugbel, F. A.
    Feng, S.
    Choi, W. J.
    Aceituno, L.
    Selzner, N.
    Jaeckel, E.
    Falla-Rad, N.
    Knox, J. J.
    Chen, E. X.
    O'Kane, G. M.
    Sapisochin, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S82 - S83
  • [43] Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma
    Yilmaz, C.
    Karaca, C. A.
    Lakobadze, Z.
    Farajov, R.
    Kilic, K.
    Doganay, L.
    Kilic, M.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (10) : 3571 - 3576
  • [44] Early recurrence of hepatocellular carcinoma after living donor liver transplantation
    Ohkubo, T
    Sugawara, Y
    Imamura, H
    Kaneko, J
    Matsui, Y
    Makuuchi, M
    HEPATO-GASTROENTEROLOGY, 2004, 51 (55) : 237 - 238
  • [45] Everolimus mitigates the risk of hepatocellular carcinoma recurrence after liver transplantation
    De Simone, Paolo
    Precisi, Arianna
    Lai, Quirino
    Ducci, Juri
    Campani, Daniela
    Marchetti, Piero
    Gitto, Stefano
    JOURNAL OF HEPATOLOGY, 2024, 80 : S456 - S456
  • [46] Recurrence After Liver Transplantation for Hepatocellular Carcinoma A New MORAL to the Story
    Halazun, Karim J.
    Najjar, Marc
    Abdelmessih, Rita M.
    Samstein, Benjamin
    Griesemer, Adam D.
    Guarrera, James V.
    Kato, Tomoaki
    Verna, Elizabeth C.
    Emond, Jean C.
    Brown, Robert S., Jr.
    ANNALS OF SURGERY, 2017, 265 (03) : 557 - 564
  • [47] Impact of donor characteristics on hepatocellular carcinoma recurrence after liver transplantation
    Akabane, Miho
    Bekki, Yuki
    Imaoka, Yuki
    Inaba, Yosuke
    Esquivel, Carlos O.
    Melcher, Marc L.
    Kwong, Allison
    Sasaki, Kazunari
    BRITISH JOURNAL OF SURGERY, 2024, 111 (04)
  • [48] Donor Quality and the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Orci, Lorenzo A.
    Majno, Pietro E.
    Lacotte, Stephanie
    Mentha, Gilles
    Toso, Christian
    LIVER TRANSPLANTATION, 2014, 20 : S148 - S149
  • [49] Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Badwei, Nourhan
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 13 (05) : 804 - 812
  • [50] Donor characteristics and the risk of hepatocellular carcinoma recurrence after liver transplantation
    Orci, Lorenzo A.
    Berney, Thierry
    Majno, Pietro Edoardo
    Lacotte, Stephanie
    Oldani, Graziano
    Morel, Philippe
    Mentha, Gilles
    Toso, Christian
    SWISS MEDICAL WEEKLY, 2014, 144 : 5S - 5S